I-309 CRISPR/Cas9 KO Plasmid (m): sc-422834
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- I-309 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the I-309 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
I-309 CRISPR/Cas9 KO Plasmid (m) | sc-422834 | 20 µg | $397.00 |
Overview
Ccl1 encodes the CC chemokine I-309, a secreted ligand that signals primarily through CCR8 to direct chemotaxis and positioning of immune cells within inflamed tissues. In mouse, CCL1 is produced by activated T cells, monocytes/macrophages, and other leukocytes, contributing to leukocyte trafficking, cytokine network coordination, and regulation of inflammatory microenvironments. This axis intersects with NF-κB–linked inflammatory programs and shapes adaptive immune responses by influencing T cell polarization and recruitment. Altered Ccl1/CCR8 signaling has been associated with models of allergic inflammation, autoimmune-like pathology, and tumor-associated immune infiltration, making it relevant for mechanistic studies of immunopathology.
I-309 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ccl1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ccl1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ccl1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish I-309 protein expression.
This CRISPR knockout system enables efficient generation of Ccl1-deficient cell models for investigation of I-309 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ccl1 exon(s) critical for I-309 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ccl1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by I-309 CRISPR/Cas9 KO Plasmid (m) and I-309 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ccl1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by I-309 HDR Plasmid (m) and I-309 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ccl1 homology arms to support homology-directed repair at defined Ccl1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.